Pharmacogenomics/pharmacoproteomics Europe

Pharmacogenomics

Volumn 3, Issue 4, 2002, Pages 449-452

  Meister, Wolfgang ^a  

^a Epidauros Biotechnologie AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; QUINOLONE; BIOLOGICAL MARKER; DRUG;

ADVERSE DRUG REACTION; ANALYTICAL ERROR; BIOINFORMATICS; CONFERENCE PAPER; DRUG INDUSTRY; DRUG LABELING; DRUG METABOLISM; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GENOME; HAPLOTYPE; HUMAN; MATHEMATICAL MODEL; MEDICAL RESEARCH; PATIENT ATTITUDE; PHARMACOGENOMICS; PHYSICIAN ATTITUDE; PROTEOMICS; SAMPLE SIZE; SYSTEM ANALYSIS; TECHNOLOGY; DRUG DESIGN; EUROPE; GENETICS; GENOTYPE; PHARMACOGENETICS; PHARMACOKINETICS;

BIOLOGICAL MARKERS; DRUG DESIGN; EUROPE; GENETIC RESEARCH; GENOTYPE; HUMAN; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PROTEOMICS; VARIATION (GENETICS); HUMANS;

EID: 0036020645     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.4.449     Document Type: Conference Paper

References (16)

1. Candidate gene approach for pharmacogenetic studies
2. Pharmacogenetics and the practice of medicine
3. The genetic basis of variability in drug responses
4. The impact of pharmacogenetics and pharmacogenomics on drug discovery
5. The use of single-nucleotide polymorphism maps in pharmacogenomics
6. Genome-and proteome-based technologies: Status and applications in the postgenomic era
7. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
8. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): Design criteria and assay validation
9. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network
10. Proteomics reveals open reading frames in Mycobacterium tuberculosis H37Rv not predicted by genomics
11. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
12. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study
13. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review
14. Pharmacogenomic-guided drug development: Regulatory perspective
15. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm
16. Personalized medicine: Revolutionizing drug discovery and patient care